APAnthony F. Pizon

Anthony F. Pizon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anthony F. Pizon has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Frank LoVecchio

    Banner Poison & Drug Information Center, Banner University Medical Center-Phoenix, Phoenix, AZ

    9 shared publications
  • Anne-Michelle Ruha

    Department of Medical Toxicology, Banner University Medical Center, Phoenix, AZ, USA

    5 shared publications
  • Bradley D. Riley

    4 shared publications
  • Daniel E. Brooks

    Banner Poison & Drug Information Center, Banner University Medical Center-Phoenix, Phoenix, AZ

    4 shared publications
  • Joseph H. Yanta

    Division of Medical Toxicology, Department of Emergency Medicine, University of Pittsburgh School of Medicine, Iroquois Building Suite 400, 3600 Forbes Ave, Pittsburgh, PA 15213, USA

    4 shared publications
  • Matthew D. Krasowski

    Department of Pathology, University of Iowa Hospitals and Clinics , Iowa City, IA

    4 shared publications

Latest Publications

  • North American Congress of Clinical Toxicology (NACCT) 2026

    by Chelsea Hayman, Kevin Brandecker, Kathy LeSaint, Craig Smollin, Aria Darling, Jennifer Thompson, Mary Green, Brandtly Yakey, David Carroll, Bram Dolcourt, et al.

    Background: Bupropion is a common cause of drug-induced seizures, but evidence guiding prophylactic therapy is limited. No prospective head-to-head comparison of phenobarbital and benzodiazepines for symptomatic bupropion overdose has been reported. Methods: We performed a 6-month prospective observational cohort study of patients with symptomatic bupropion overdose. Patients were grouped by receipt of seizure prophylaxis versus no prophylaxis, with agent-specific exploratory analyses for phenobarbital and lorazepam. Baseline characteristics and clinical outcomes were summarized using descriptive statistics. Continuous variables were assessed for normality using Shapiro-Wilk testing and summarized as median and interquartile range (IQR) when non-normally distributed. Categorical outcomes were compared using two-tailed Fisher exact tests with statistical significance defined as p < 0.05. Exploratory logistic regression evaluated seizure odds by prophylaxis group with and without adjustment for initial heart rate. Results: Fifty-five patients were enrolled: 39 received prophylaxis and 16 who did not receive recommended prophylaxis and served as controls. The prophylaxis agents used were phenobarbital in 20 patients, lorazepam in 12, other benzodiazepines in 6, and combined phenobarbital plus lorazepam in 1. Initial heart rate was 114 bpm (IQR 97–133.5) in the prophylaxis group versus 109 bpm (IQR 103.5–117.8) in controls. Reported ingestion dose was 2.70 g (IQR 1.39–5.18) versus 1.80 g (IQR 0.98–7.13), respectively. Three patients had a documented seizure history and were in the prophylaxis group, none of which experienced a seizure. Overall seizure incidence was lower with prophylaxis but did not reach statistical significance (1/39 [2.6%] vs 3/16 [18.8%]; p = 0.069). Proconvulsant co-ingestions were similar between groups (12/39 [30.8%] vs 7/16 [43.8%]; p = 0.370). Among patients with known ingestion ≥3 g, seizures occurred in 0/10 phenobarbital-treated patients, 1/4 lorazepam-treated patients, and 3/5 controls; phenobarbital differed from control (p = 0.022), whereas lorazepam did not (p = 0.524), and phenobarbital did not differ significantly from lorazepam (p = 0.286). Among patients with initial heart rate ≥120 bpm, seizures occurred in 0/7 phenobarbital-treated patients, 1/6 lorazepam-treated patients, and 3/4 controls; phenobarbital differed from control (p = 0.024), whereas lorazepam did not (p = 0.190) and phenobarbital did not differ significantly from lorazepam (p = 0.462). Exploratory logistic regression adjusted for initial heart rate found higher seizure odds in controls than in prophylaxis patients (OR 26.86, 95% CI 1.21–598.08; p = 0.038); initial heart rate showed a nonsignificant trend (OR 1.08 per bpm; p = 0.070). Conclusions: In this interim cohort, phenobarbital was associated with fewer seizures than no prophylaxis in higher-risk subgroups. However, direct phenobarbital-lorazepam comparisons were not statistically different. Findings remain hypothesis-generating given the small sample, observational design, statistical fragility, sparse seizure events, wide regression confidence intervals, and potential reporting bias. Background: Bromadiolone is a long-acting anticoagulant rodenticide that can cause severe and prolonged coagulopathy in humans, while clinical data from low- and middle-income countries remain limited. This study aimed to describe the clinical characteristics, laboratory findings, management strategies, and outcomes of patients with bromadiolone poisoning treated at an emergency center in Vietnam, and to identify factors associated with severe outcomes. We conducted a retrospective observational study of adult patients with confirmed bromadiolone poisoning admitted to the Emergency Center of Thai Nguyen Medical University Hospital, Vietnam, between February 2021 and August 2024. Demographic data, exposure characteristics, clinical manifestations, laboratory parameters, treatment details, and outcomes were extracted from medical records. Severe outcome was defined as major bleeding, international normalized ratio (INR) ≥ 5, requirement for blood product transfusion, or death. A total of 33 patients were included, with a median age of 46 years; 60.6% were male, and suicidal ingestion accounted for 66.7% of cases. Severe outcomes occurred in 7 patients (21.2%). Patients with severe outcomes presented significantly later after exposure (median 48 vs. 5.5 h, p = 0.001) and had markedly higher admission INR values. Bleeding manifestations and blood product transfusion were observed exclusively in the severe outcome group, and no in-hospital deaths occurred. In conclusion, bromadiolone poisoning is associated with substantial morbidity due to prolonged coagulopathy. Delayed hospital presentation and severe coagulopathy at admission are strongly associated with adverse outcomes, highlighting the importance of early recognition and appropriate vitamin K therapy in resource-limited settings. Methods: This retrospective observational study was conducted at the Emergency Center of Thai Nguyen Medical University Hospital, Thai Nguyen, Vietnam. Study population: All consecutive adult patients diagnosed with bromadiolone poisoning and admitted between February 2021 and August 2024 were eligible. Inclusion criteria: Exclusion criteria: Data collection Data extracted from medical records included: Results: Baseline characteristics: Thirty-three patients with bromadiolone poisoning were included. The median age was 46 years (IQR 27), and 20 patients (60.6%) were male. Suicidal ingestion was the most common exposure intent, accounting for 22 cases (66.7%). The median time from exposure to hospital presentation was 7 h (IQR 20), and the median estimated ingestion dose was 1 mg (IQR 4). Conclusions: Bromadiolone poisoning is a serious clinical condition associated with prolonged coagulopathy and a substantial risk of severe bleeding. Delayed hospital presentation and severe coagulopathy at admission are strongly associated with adverse outcomes. Early diagnosis, close monitoring of coagulation parameters, and appropriate vitamin K therapy are essential to improve outcomes, particularly in low- and middle-income countries. Background: Amiodarone is an antiarrhythmic drug used to treat life-threatening cardiac dysrhythmias, but its use is limited by multiorgan toxicity. Large-scale age-stratified data on clinical outcomes remain limited. The National Poison Data System (NPDS) is a national database of over 81 million de-identified case records from all 53 U.S. poison centers. The objective of this study was to describe amiodarone exposures reported to U.S. poison centers.

  • Open Access

    Antimuscarinic delirium in a pediatric patient reversed with transdermal rivastigmine: A case report

    by Natalie E. Ebeling-Koning, Natalie A. Burkert, Laura Koons, John D. Lindmark, Anthony F. Pizon, Kenneth D. Katz

  • Transdermal buprenorphine patch-facilitated induction of sublingual buprenorphine in hospitalized patients receiving full agonist opioids: a retrospective cohort study

    by Simon J. Ostrowski, Alek Adkins, David Goldfarb, Melissa Kukowski, Darien Stratton, David J. Barton, Anthony F. Pizon

    Treatment with buprenorphine is challenging to initiate in hospitalized patients receiving full agonist opioids because of the risk of precipitated opioid withdrawal. We describe clinical outcomes of precipitated withdrawal, incidence and rate of buprenorphine prescription at discharge in hospitalized patients undergoing transdermal buprenorphine patch-facilitated buprenorphine induction while receiving full agonist opioids. This is a retrospective chart review of hospitalized patients in a single academic healthcare system who were started on sublingual buprenorphine for opioid use disorder using a transdermal buprenorphine patch low-dose initiation strategy with overlapping full agonist opioids. The primary outcome was incidence of precipitated opioid withdrawal among those who received at least one dose of sublingual buprenorphine following low-dose initiation. Discharge with a prescription for sublingual buprenorphine was a secondary outcome. Of 288 unique patient encounters with inpatient buprenorphine patch use, 68 met eligibility criteria for inclusion and five of 68 (7.4%, 95% CI: 2.4-16.3%) experienced precipitated opioid withdrawal. Sixty-seven of 68 (99%) patients were discharged with a buprenorphine prescription including 100% of those with precipitated withdrawal. There were no significant associations between incidence of precipitated withdrawal and oral morphine equivalents received prior to sublingual buprenorphine induction, age, sex, history of liver disease, dose or duration of transdermal buprenorphine patch. This study supports growing evidence that a transdermal buprenorphine patch-facilitated buprenorphine initiation strategy in hospitalized patients receiving full agonist opioids is well-tolerated. Limitations include its retrospective chart review methodology and incomplete data available to fully characterize precipitated withdrawal. Transdermal buprenorphine-facilitated low dose buprenorphine initiation in hospitalized patients receiving full agonist opioids was well-tolerated in the majority of patients, with 7.4% (95% CI: 2.4-16.3%) developing precipitated withdrawal.


  • The Value of Medical Toxicologists

    by Paul M. Wax, Tracy M. Kolian, Anthony F. Pizon

    Poisoning is a major public health issue and one of the leading causes of injury related death in the US. Poisonings result from intentional or unintentional use of prescription drugs or illicit overdose including opioids, inhalation of toxic fumes, ingestion of contaminated food or drinking water, and envenomations. The cost of poisonings to US health care is large, especially when considering the costs of addiction and illicit opioids. As specially trained physicians, medical toxicologists play a major role in the treatment and care of poisoned patients while improving patient care, population health, and health care systems related to chemical exposures and poisonings including prevention. They also play a major role in the opioid epidemic and in caring for patients with opioid use disorder and substance use disorders more broadly. Regardless of these important roles, the recognition and knowledge of the value that medical toxicologists provide to health and the health care system is limited. As reimbursement becomes linked to outcome in a value-based care (VBC) market, medical toxicologists must continue to demonstrate their value to stakeholders. The American College of Medical Toxicology (ACMT) has long recognized the need for medical toxicologists to articulate their value and to advocate for themselves, the profession, and for the patients they serve. To that end, modeling infectious disease (ID) efforts in establishing value for their specialty, this paper outlines the ‘value’ of medical toxicologists in improving patient outcomes, and their positive impact on population health and health care systems.


  • Occult bromazolam exposure in patients presenting with opioid or stimulant overdose

    by Adenine Cembellin-Kao, Kim Aldy, Jeffrey Brent, Rachel Culbreth, Crystal LaBozzetta, Miguel Alexander Turcios, Paul Wax, Chase Yonamine, Andrew Stolbach, Stephanie Abston, et al.

    Bromazolam is a benzodiazepine, not approved for use in any North American or European jurisdiction that has emerged as an adulterant in the United States illicit drug supply. This is a case series of seven patients treated for an acute overdose and found to have bromazolam in their blood despite no self-reported exposure. Patients were enrolled from June 2023 to January 2024 as part of the Drug Overdose Toxico-Surveillance Reporting Program, a multi-center, prospective project including patients aged 13 years and older with a suspected life-threatening opioid and/or stimulant overdose. This case series is drawn from a single emergency department from that project. Patients were interviewed on their drug use, and clinical data were collected from electronic medical records. Whole blood was obtained and tested qualitatively for over 1,200 psychoactive substances using liquid chromatography quadrupole time-of-flight mass spectrometry and quantitative measurements using liquid chromatography-tandem quadrupole mass spectrometry. Patients presented with acute signs of excessive sedation (six of seven) or agitation (one of seven). The median blood bromazolam concentration was 29 µg/L (range <5-84 µg/L). Three patients were admitted to hospital or observed for more than 24 h in the emergency department. The reasons for admission/observation were advanced pregnancy, prolonged sedation, and the need for social services. No patients were placed in a critical care unit and all patients survived. During the structured interview, none of the patients reported bromazolam use. This case series demonstrated no poor clinical outcomes in patients with acute overdose who had detectable bromazolam concentrations despite no reported bromazolam use. In all cases of sedation, patients responded to naloxone (in all cases the patients admitted to taking opioids, which was confirmed analytically), and there was no ongoing sedation attributed to the detected bromazolam. Substances unknown to patients are present in the drug supply. Toxico-surveillance programs are essential to obtaining information about community patterns of drug use that cannot be obtained from patient history or from medical charts.


  • Lipid emulsion therapy during management of the critically-ill poisoned patient: a prospective cohort study

    by Michael Levine, Jeffrey Brent, Timothy Wiegand, Bryan Maguire, Neta Cohen, David Vaerrier, Michael Beuhler, Jerrold B. Leikin, Michael Ganetsky, Samuel Stellpflug, et al.

    Despite conflicting data, intravenous lipid emulsion has emerged as a potential antidote. The "lipid sink" theory suggests that following intravenous administration of lipid, lipophilic drugs are sequestered in the vascular compartment, thereby reducing their tissue concentrations. This study sought to determine if survival is associated with the intoxicant's degree of lipophilicity. We reviewed all cases in the Toxicology Investigators Consortium's lipid sub-registry between May 2012 through December 2018. Information collected included demographics, exposure circumstances, clinical course, management, disposition, and outcome. The primary outcome was survival after lipid emulsion therapy. Survival was stratified by the log of the intoxicant's octanol-water partition coefficient. We also assessed the association between intoxicant lipophilicity and an increase in systolic blood pressure after lipid emulsion administration. We identified 134 patients, including 81 (60.4%) females. The median age was 40 years (interquartile range 21-75). One hundred and eight (80.6%) patients survived, including 45 (33.6%) with cardiac arrest during their intoxication. Eighty-two (61.2%) were hypotensive, and 98 (73.1%) received mechanical ventilation. There was no relationship between survival and the log of the partition coefficient of the intoxicant on linear analysis (P = 0.89) or polynomial model (P = 0.10). Systolic blood pressure increased in both groups. The median (interquartile range) systolic blood pressure before lipid administration was 68 (60-78) mmHg for those intoxicants with a log partition coefficient < 3.6 compared with 89 (76-104) mmHg after lipid administration. Among those drugs with a log partition coefficient > 3.6, the median (interquartile range) was 69 (60-84) mmHg before lipid and 89 (80-96) mmHg after lipid administration. Most patients in this cohort survived. Lipophilicity was not correlated with survival or the observed changes in blood pressure. The study did not address the efficacy of lipid emulsion.


  • Heart-Brain 346-7 Score: the development and validation of a simple mortality prediction score for carbon monoxide poisoning utilizing deep learning

    by Jason J. Rose, Michael S. Zhang, Jerry Pan, Marc C. Gauthier, Anthony F. Pizon, Melissa I. Saul, Seyed M. Nouraie


  • Open Access

    Demand for Medical Toxicology Fellowship Training Is at an All-Time High

    by Anthony F. Pizon, Louise Kao, Mark B. Mycyk, Paul M. Wax